Soft Tissue Sarcoma ceRNA Network and Biomarkers from TCGA RNA-Seq Analysis

Dandan Zou from Harbin Medical University analyzed RNA sequencing data from The Cancer Genome Atlas (TCGA) for soft tissue sarcoma patients. The study identified 328 differentially expressed mRNAs, 18 miRNAs, and 67 lncRNAs, constructing a competing endogenous RNA (ceRNA) network and protein-protein interaction network. It validated the expression of five specific mRNAs (APOL1, EFEMP1, LYZ, RARRES1, TNFAIP2) and identified several biomarkers associated with patient survival.

Use Cases

• Identify prognostic biomarkers for soft tissue sarcoma based on the 328 differentially expressed mRNAs, 18 miRNAs, and 67 lncRNAs.
• Analyze competing endogenous RNA (ceRNA) regulatory networks in the tumor microenvironment using the established network.
• Validate gene expression findings for specific mRNAs like APOL1, EFEMP1, LYZ, RARRES1, and TNFAIP2 mentioned in the study.
• Explore associations between immune/stromal scores and overall survival in soft tissue sarcoma patients.
• Perform gene set enrichment analysis (GSEA) on lncRNAs to investigate immune response-associated pathways.

Strengths

• Analysis is based on RNA sequencing data from the authoritative The Cancer Genome Atlas (TCGA) database.
• Identified specific counts of molecular features: 328 differentially expressed mRNAs, 18 miRNAs, and 67 lncRNAs.
• Validated the expression levels of five specific mRNAs (APOL1, EFEMP1, LYZ, RARRES1, TNFAIP2) against the TCGA cohort.

Limitations

• Row count and dataset size are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

The Cancer Genome Atlas (TCGA) database, analyzed by Dandan Zou (Harbin Medical University).

Collection Method

RNA sequencing data analysis using the ESTIMATE algorithm for immune/stromal scores, followed by differential expression and network analysis.